About V-Wave
V-Wave is a company based in Caesarea (Israel) founded in 2009 was acquired by Johnson & Johnson in August 2024. V-Wave has raised $128 million across 4 funding rounds from investors including Johnson & Johnson, Edwards Lifesciences and Deerfield. V-Wave offers products and services including Ventura Interatrial Shunt System. V-Wave operates in a competitive market with competitors including Sequana Medical, CVRx, HeartWare, Element Science and Ancora Heart, among others.
- Headquarter Caesarea, Israel
-
Sectors
Healthcare
-
Phone
Locked
-
Website
Locked
-
Social
Locked
- Legal Name V-Wave Limited
-
Annual Revenue
Not available
-
Net Profit
Not available
-
EBITDA
Not available
-
Total Equity Funding
$128 M (USD)
in 4 rounds
-
Latest Funding Round
$28 M (USD), Series C
Sep 23, 2020
-
Investors
Johnson & Johnson
& 13 more
-
Employee Count
Not available
-
Acquired by
Johnson & Johnson
(Aug 20, 2024)
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Products & Services of V-Wave
V-Wave offers a comprehensive portfolio of products and services, including Ventura Interatrial Shunt System.
Device improves blood flow for heart failure patients through innovative shunt technology.
People of V-Wave
Unlock access to complete
Funding Insights of V-Wave
V-Wave has successfully raised a total of $128M across 4 strategic funding rounds. The most recent funding activity was a Series C round of $28 million completed in September 2020. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
Investors in V-Wave
V-Wave has secured backing from 14 investors, including venture fund and institutional investors. Prominent investors backing the company include Johnson & Johnson, Edwards Lifesciences and Deerfield.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Healthcare ecosystem is supported through investment and innovation by Deerfield.
|
Locked | Locked | Locked | |
|
Endeavour Vision is focused on transformative healthcare technology investments.
|
Locked | Locked | Locked | |
|
Tech & Life Sciences focused early stage VC firm investing in North America
|
Locked | Locked | Locked |
Investor details for V-Wave
Investor domains, locations, round participation, and complete history require an active premium plan.
- Investor domains
- Investor locations
- Funding rounds
- Participation history
Verified entity values are shown only after access is granted.
Investments & Acquisitions by V-Wave
Investment portfolio details for V-Wave
Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.
- Portfolio identities
- Transaction dates
- Round details
- Investment values
Verified entity values are shown only after access is granted.
Financial Statements - V-Wave
Detailed financials for V-Wave
Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.
- Historical revenue
- Profit trends
- Statement rows
- Financial ratios
Verified entity values are shown only after access is granted.
V-Wave Comparisons
Peer comparison for V-Wave
Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.
- Named peers
- Headcount comparison
- Funding comparison
- Operating benchmarks
Verified entity values are shown only after access is granted.
Competitors of V-Wave
V-Wave operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Sequana Medical, CVRx, HeartWare, Element Science and Ancora Heart, among others.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| Locked | Locked | Locked |
Implantable battery-powered pumps for ascites removal are developed.
|
|
| Locked | Locked | Locked |
Implantable technology for hypertension and heart failure is developed.
|
|
| Locked | Locked | Locked |
Miniaturized ventricular assist devices are developed for heart failure treatment.
|
|
| Locked | Locked | Locked |
Wearable patch defibrillators are developed for sudden cardiac arrest treatment.
|
|
| Locked | Locked | Locked |
Minimally invasive ventriculoplasty system for heart failure and FMR
|
|
| Locked | Locked | Locked |
Total artificial hearts are developed for cardiac replacement therapy.
|
Detailed competitors of V-Wave
Competitor domains, locations, full profiles, and operating metrics require an active premium plan.
- Domains and locations
- Full company profiles
- Operating metrics
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on V-Wave
Complete news archive for V-Wave
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about V-Wave
V-Wave was founded in 2009 and raised its 1st funding round 4 years after it was founded.
V-Wave is headquartered in Caesarea, Israel. It is registered at Caesarea, Haifa, Israel.
V-Wave is a funded company, having raised a total of $128M across 4 funding rounds to date.
V-Wave was founded in 2009 in Caesarea, Israel, within the medical devices sector. Percutaneous implantable devices are developed by the company to address chronic heart failure in patients. An inter-atrial shunt is offered as a key product to regulate left atrial pressure and alleviate symptoms. FDA approval has been secured for this device, supporting its clinical use.
V-Wave's top competitors include Sequana Medical, CVRx and Adona Medical.
V-Wave offers Ventura Interatrial Shunt System.
V-Wave has 14 investors. Key investors include Johnson & Johnson, Edwards Lifesciences, Deerfield, Endeavour Vision, and Quark Venture.